IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)ACR50 AND ACR70 RESPONSE RATES1-3

P<0.0001 vs placebo.

*The same patients may not have responded at each timepoint.

ACR50 responses in DISCOVER 2 at Weeks 16 and 24 were not part of sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 at Week 24.

#P<0.001 vs placebo.
**P=0.036 vs placebo.

ACR50 responses in DISCOVER 1 at Weeks 16 and 24 were not part of sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 at Week 24.

Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.
§After Week 24, patients and doctors knew that all patients were on TREMFYA® (open-label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analysis from Weeks 24 to 52 is not shown.

P<0.001 vs placebo.

*Same patients may not have responded at each timepoint.

ACR70 responses in DISCOVER 2 at Week 24 were not part of sequential testing procedure but were prespecifited to be tested upon achieving statistical significance for ACR20.

ACR70 responses in DISCOVER 2 at Week 16 was not controlled for multiplicity. Therefore, statistical significance has not been established.

#P=0.069 vs placebo.

ACR70 responses in DISCOVER 1 at Week 24 were not part of sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20.

ACR70 responses in DISCOVER 1 at Week 16 was not controlled for multiplicity. Therefore, statistical significance has not been established.

NS=Not significant.
Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.
§After Week 24, patients and doctors knew that all patients were on TREMFYA® (open-label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analysis from Weeks 24 to 52 is not shown.

References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 4. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125.